These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23969780)

  • 1. Use of prolactin receptor antagonist to better understand prolactin regulation of pituitary homeostasis.
    Ferraris J; Bernichtein S; Pisera D; Goffin V
    Neuroendocrinology; 2013; 98(3):171-9. PubMed ID: 23969780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolactin receptor antagonism in mouse anterior pituitary: effects on cell turnover and prolactin receptor expression.
    Ferraris J; Boutillon F; Bernadet M; Seilicovich A; Goffin V; Pisera D
    Am J Physiol Endocrinol Metab; 2012 Feb; 302(3):E356-64. PubMed ID: 22094470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin induces apoptosis of lactotropes in female rodents.
    Ferraris J; Zárate S; Jaita G; Boutillon F; Bernadet M; Auffret J; Seilicovich A; Binart N; Goffin V; Pisera D
    PLoS One; 2014; 9(5):e97383. PubMed ID: 24859278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactin receptor antagonism uncouples lipids from atherosclerosis susceptibility.
    van der Sluis RJ; van den Aardweg T; Reuwer AQ; Twickler MT; Boutillon F; Van Eck M; Goffin V; Hoekstra M
    J Endocrinol; 2014 Sep; 222(3):341-50. PubMed ID: 25063756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autocrine actions of prolactin contribute to the regulation of lactotroph function in vivo.
    Bernard V; Lamothe S; Beau I; Guillou A; Martin A; Le Tissier P; Grattan D; Young J; Binart N
    FASEB J; 2018 Sep; 32(9):4791-4797. PubMed ID: 29596024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and thermodynamic bases for the design of pure prolactin receptor antagonists: X-ray structure of Del1-9-G129R-hPRL.
    Jomain JB; Tallet E; Broutin I; Hoos S; van Agthoven J; Ducruix A; Kelly PA; Kragelund BB; England P; Goffin V
    J Biol Chem; 2007 Nov; 282(45):33118-31. PubMed ID: 17785459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies.
    Standing D; Dandawate P; Anant S
    Front Endocrinol (Lausanne); 2022; 13():1112987. PubMed ID: 36714582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in prolactin receptor (PRLR) in mouse and human fallopian tubes: evidence for multiple regulatory mechanisms controlling PRLR isoform expression in mice.
    Shao R; Nutu M; Weijdegård B; Egecioglu E; Fernandez-Rodriguez J; Tallet E; Goffin V; Ling C; Billig H
    Biol Reprod; 2008 Oct; 79(4):748-57. PubMed ID: 18596217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
    Llovera M; Pichard C; Bernichtein S; Jeay S; Touraine P; Kelly PA; Goffin V
    Oncogene; 2000 Sep; 19(41):4695-705. PubMed ID: 11032019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The many faces of prolactin in breast cancer.
    Chen WY
    Adv Exp Med Biol; 2015; 846():61-81. PubMed ID: 25472534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prolactin (PRL)--multifunctional, hypophyseal peptide hormone].
    Michalik J; Bartoszewicz Z
    Postepy Biochem; 2002; 48(4):296-305. PubMed ID: 12731395
    [No Abstract]   [Full Text] [Related]  

  • 12. A major prolactin-binding complex on human milk fat globule membranes contains cyclophilins A and B: the complex is not the prolactin receptor.
    Lorenson MY; Ueda EK; Chen KE; Walker AM
    Am J Physiol Endocrinol Metab; 2012 Mar; 302(5):E585-94. PubMed ID: 22205628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Action mechanism of pituitary hormones--receptor and signal transduction--prolactin].
    Aono T; Yokoyama Y
    Nihon Rinsho; 1993 Oct; 51(10):2631-5. PubMed ID: 8254931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
    Beck MT; Chen NY; Franek KJ; Chen WY
    Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactin and the prolactin receptor: new targets of an old hormone.
    Harris J; Stanford PM; Oakes SR; Ormandy CJ
    Ann Med; 2004; 36(6):414-25. PubMed ID: 15513293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.
    Gutzman JH; Miller KK; Schuler LA
    J Steroid Biochem Mol Biol; 2004 Jan; 88(1):69-77. PubMed ID: 15026085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2/STAT5 Pathway Mediates Prolactin-Induced Apoptosis of Lactotropes.
    de Dios N; Orrillo S; Irizarri M; Theas MS; Boutillon F; Candolfi M; Seilicovich A; Goffin V; Pisera D; Ferraris J
    Neuroendocrinology; 2019; 108(2):84-97. PubMed ID: 30376668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin receptor antagonists.
    Kuo CB; Coss D; Walker AM
    Endocrine; 1998 Oct; 9(2):121-31. PubMed ID: 9867245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of new prolactin analogs acting as pure prolactin receptor antagonists.
    Goffin V; Bernichtein S; Kayser C; Kelly PA
    Pituitary; 2003 Sep; 6(2):89-95. PubMed ID: 14703018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactin stimulates cell proliferation through a long form of prolactin receptor and K+ channel activation.
    Van Coppenolle F; Skryma R; Ouadid-Ahidouch H; Slomianny C; Roudbaraki M; Delcourt P; Dewailly E; Humez S; Crépin A; Gourdou I; Djiane J; Bonnal JL; Mauroy B; Prevarskaya N
    Biochem J; 2004 Feb; 377(Pt 3):569-78. PubMed ID: 14565846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.